Aviceda Therapeutics
Last verified 2026-05-07. JSON
The funding figures on this page are attributed, not sourced: a publisher is on record but no document URL is. How we mark provenance.
| Total raised | $300.0Mattributed |
|---|---|
| Latest round | series-c, $208.0M, 2025-01-08attributed |
| Founded | 2018 |
| Headquarters | Cambridge |
| Industry | bio |
| Stage | series-b+ |
| Website | avicedatx.com |
Clinical-stage biotech building glyco-immune therapeutics using its HALOS Siglec-targeting platform to modulate the innate immune system. Targets patients with geographic atrophy, retinal disease and chronic inflammatory conditions. Lead asset AVD-104 is in Phase 2b for geographic atrophy with about 300 patients enrolled across three arms.
Funding rounds
| Date | Round | Amount | Lead |
|---|---|---|---|
| 2025-01-08 | series-c | $208.0M | undisclosed |
Provenance
| Fact | Status | Basis |
|---|---|---|
| Series C, $208.0M | attributed | crunchbase named as publisher. No document URL on file. |
| Total raised $300.0M | attributed | crunchbase named as publisher. No document URL on file. |
| Company existence | self-reported | avicedatx.com, read 2026-05-07 |
| Description | self-reported | avicedatx.com, read 2026-05-07 |
Nothing on this page is sourced yet. A sourced fact links to a document that states it.
Change history
No change recorded since records began on 2026-09-24.